Codera, LLC

CODA Biotherapeutics, Inc. is a South San Francisco-based preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform to treat neurological disorders, with an initial focus on intractable neuropathic pain and epilepsy. Its platform uses AAV viral vectors to deliver genes encoding engineered, tunable ligand-gated ion channels in target neurons, which can then be activated or silenced by orally bioavailable small-molecule drugs.